Free Trial

X4 Pharmaceuticals (XFOR) SEC Filings & 10K Form

X4 Pharmaceuticals logo
$0.27 +0.00 (+0.63%)
Closing price 04:00 PM Eastern
Extended Trading
$0.27 +0.00 (+0.33%)
As of 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Recent X4 Pharmaceuticals SEC Filings

DateFilerForm TypeView
03/26/2025
5:12 AM
X4 Pharmaceuticals (Filer)
Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans  
03/25/2025
6:51 AM
X4 Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
03/24/2025
3:43 PM
X4 Pharmaceuticals (Filer)
Form DEF 14A
02/06/2025
3:06 PM
X4 Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
01/31/2025
9:09 AM
VANGUARD GROUP INC (Filed by)
X4 Pharmaceuticals (Subject)
Form SCHEDULE 13G/A
01/27/2025
5:15 PM
Arbet-Engels Christophe (Reporting)
X4 Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
01/27/2025
5:15 PM
DiBiase Mary (Reporting)
X4 Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
01/27/2025
5:15 PM
Baldry Mark (Reporting)
X4 Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
01/27/2025
5:15 PM
Mostafa Adam S. (Reporting)
X4 Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
01/27/2025
5:15 PM
Ragan Paula (Reporting)
X4 Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
01/24/2025
3:17 PM
Taveras Arthur (Reporting)
X4 Pharmaceuticals (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/24/2025
3:18 PM
DiBiase Mary (Reporting)
X4 Pharmaceuticals (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/24/2025
3:21 PM
Mostafa Adam S. (Reporting)
X4 Pharmaceuticals (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/24/2025
3:22 PM
Ragan Paula (Reporting)
X4 Pharmaceuticals (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/16/2025
3:45 PM
X4 Pharmaceuticals (Filer)
Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans  
01/13/2025
6:50 AM
X4 Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/13/2024
8:02 AM
X4 Pharmaceuticals (Filer)
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
11/13/2024
7:11 AM
X4 Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/13/2024
5:12 AM
X4 Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/04/2024
1:15 PM
VANGUARD GROUP INC (Filed by)
X4 Pharmaceuticals (Subject)
Form SC 13G/A
10/22/2024
5:06 PM
BlackRock, Inc. (Filed by)
X4 Pharmaceuticals (Subject)
Form SC 13G
10/16/2024
3:54 PM
Ragan Paula (Reporting)
X4 Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
10/15/2024
3:07 PM
Ragan Paula (Reporting)
X4 Pharmaceuticals (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
10/08/2024
3:44 PM
Taveras Arthur (Reporting)
X4 Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
10/08/2024
3:44 PM
DiBiase Mary (Reporting)
X4 Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
10/08/2024
3:44 PM
Ragan Paula (Reporting)
X4 Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
10/08/2024
3:44 PM
Baldry Mark (Reporting)
X4 Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
10/08/2024
3:44 PM
Mostafa Adam S. (Reporting)
X4 Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
10/04/2024
3:56 PM
X4 Pharmaceuticals (Filer)
Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans  
09/11/2024
3:01 PM
DiBiase Mary (Reporting)
X4 Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
08/09/2024
3:28 PM
X4 Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
08/08/2024
5:40 AM
X4 Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
07/19/2024
7:17 AM
X4 Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
06/27/2024
7:01 AM
X4 Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/22/2024
7:09 AM
X4 Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/09/2024
5:58 AM
X4 Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/07/2024
3:23 PM
X4 Pharmaceuticals (Filer)
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
05/07/2024
5:28 AM
X4 Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
04/29/2024
7:30 AM
X4 Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
04/29/2024
5:30 AM
X4 Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
04/05/2024
3:30 PM
X4 Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
A brutally honest economic warning for 2025 (see proof) (Ad)

New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked side-by-side with figures like Warren Buffett, Alan Greenspan, Ron Paul, Jim Rickards, and Steve Forbes, to name but a few) says....

04/01/2024
8:20 AM
X4 Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
(Data available from 1/1/2016 forward)

Remove Ads

Related Companies and Tools


This page (NASDAQ:XFOR) was last updated on 3/27/2025 by MarketBeat.com Staff
From Our Partners